1) first episode major depression
首发重性抑郁症
1.
1H-MRS in frontal lobe and hippocampus of patients with first episode major depression;
首发重性抑郁症患者双侧额叶和海马的磁共振质子波谱成像
2.
~1H-MRS in bilaterlis frontal lobe and hippocampus of patients with first episode major depression after SSRIs antidepressant treatment;
SSRIs抗抑郁药治疗首发重性抑郁症患者前后双侧额叶和海马~1H-MRS的分析
2) First-episode depression
首发抑郁症
1.
Comparisons of citalopram and fluoxetine in first-episode depression;
西酞普兰与氟西汀治疗首发抑郁症疗效比较
2.
Study of metabolism of glucose and lipid in patients with first-episode depression
首发抑郁症患者糖脂代谢研究
3.
Objective To evaluate the curative effects and adverse reactions of citalopram in first-episode depression.
目的评价西酞普兰治疗首发抑郁症的疗效与不良反应。
3) Major depression
重性抑郁症
1.
The Study of Personality among Different Stages of Major Depression;
重性抑郁症患者不同病期人格特征研究
2.
Association Analysis between the Norepinephrine Transporter Gene, Social Psychic Factors, Their Interaction and Major Depression;
NET基因、社会心理因素及其交互作用与重性抑郁症的关联研究
3.
Objective:Using neuropsychological tests to assess the cognitive functions of major depression(MD)and analyze the relationship between the cognitive impairment and the alternation of serum cortisol level.
目的 :探讨重性抑郁症患者神经心理学和皮质醇浓度的相关性。
4) major depression disorder(MDD)
重症抑郁性障碍
1.
Desvenlafaxine succinate,produced by Wyethpharms Inc,is approved by the US FDA for the treatment of major depression disorder(MDD).
琥珀酸去甲文拉法辛(desvenlafaxine succinate,商品名为Pristiq)于2008年2月29日经美国FDA批准上市,由美国Wyethpharms inc公司生产,用于治疗重症抑郁性障碍(MDD)。
6) Recurrent depression
复发性抑郁症
1.
Objective To explore the efficacy and safety of trazodone in the treatment of Recurrent depression.
目的探讨三唑酮治疗复发性抑郁症的疗效与安全性。
补充资料：首发
1.头发。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条